Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304190 | 0.83 | ESR1 (0.50) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL1115573 | 0.81 | HDAC8 (0.47) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL16968263 | 0.79 | HDAC8 (0.45) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL4251026 | 0.78 | ESR1 (0.52) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL1600128 | 0.77 | CHRM3 (0.33) | ESR1ESR2SYK | |
| SCHEMBL3966160 | 0.76 | HDAC8 (0.52) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL548600 | 0.76 | KIF11 (0.50) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL6933042 | 0.76 | ESR1 (0.61) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL6928370 | 0.76 | ESR1 (0.45) | ESR1ESR2ACHEHDAC4HDAC2 | |
| SCHEMBL22013510 | 0.75 | GABRA1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022081912-A2 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3407877-B1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RES & DEV (FR) | 2020-03-04 | — | — | EP | disclosed |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| CN-102482210-B | Vitamin D receptor agonists and uses thereof | VIDASYM LLC | 2015-04-08 | — | — | CN | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2419403-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | Vidasym, Llc (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120698-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-0944592-B1 | VITAMIN D3 DERIVATIVES | LEO PHARMA AS WITH SECONDARY N (DK) | 2005-01-26 | — | — | EP | disclosed |
| US-20020103172-A1 | VITAMIN D3 DERIVATIVES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIEDELSKAB) (DK) | 2002-08-01 | — | — | US | disclosed |
| EP-0944592-A1 | VITAMIN D3 DERIVATIVES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998024762-A1 | VITAMIN D3 DERIVATIVES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | ESR1 507/4885ESR2 373/4885ACHE 4732/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | ESR1 676/4885ESR2 319/4885ACHE 4542/4885 |
| US-20020103172-A1 | VITAMIN D3 DERIVATIVES | VDR, CYP24A1, CCND3 | ESR1 119/4885ESR2 97/4885ACHE 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.